Kura Oncology saw the highest growth of 0.99% in patent filings in June and 0.49% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Kura Oncology’s patent filings and grants. Buy the databook here.
Kura Oncology has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent grants with nearly 67% of grants. The World Intellectual Property Organization(WIPO), Australia(AU), Israel(IL), and United States(US) patent Office are among the top ten patent offices where Kura Oncology is filings its patents. Among the top granted patent authorities, Kura Oncology has 67% of its grants in United States(US) and 33% in Canada(CA).
Roche could be the strongest competitor for Kura Oncology
Patents related to genomics and rare diseases lead Kura Oncology's portfolio
Kura Oncology has the highest number of patents in genomics followed by, rare diseases. For genomics, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Leukemia related patents lead Kura Oncology portfolio followed by obsessive-compulsive disorder, and diabetes
Kura Oncology has highest number of patents in leukemia followed by obsessive-compulsive disorder, diabetes, acute lymphocytic leukemia (all, acute lymphoblastic leukemia), and ewing sarcoma. For leukemia, nearly 50% of patents were filed and 33% of patents were granted in Q2 2024.
For comprehensive analysis of Kura Oncology's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.